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Abstract 
 
Introduction: Drug-Induced Liver Injury (DILI) challenges drug development, clinical practice 
and drug safety regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data to 
support the study of DILI.  
Areas Covered: The LTKB brings together diverse data sources that can be used to assess and 
predict DILI. Among the extensive information available, reference drug lists with annotated 
human DILI risk are of great value. The LTKB DILI classification describes DILI severity concern 
(most, less and no DILI-concern) determined by integrating FDA drug labeling, DILI severity 
score from the NIH LiverTox database, and other DILI classification schemes described in 
published literature. Overall, over 1000 drugs are described in at least one classification 
scheme, and around 750 drugs were flagged for some degree of DILI risk.  
Expert Commentary: The LTKB provides a centralized repository of information for the study of 
DILI and the development of predictive models. DILI classification data in LTKB could be a useful 
resource to connect phenotype with molecular and mechanistic data for developing 
biomarkers, predictive models and assessing data from emerging technologies such as high-
throughput screening, high-content screening and in silico methodologies. In coming years, 
streamlining the prediction process by including DILI predictive models for both DILI severity 
and also including DILI types in LTKB would enhance the identification of chemicals with the 
potential to cause DILI earlier in drug development and risk assessment.   
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1. Introduction 
Safety and toxicity is one of the main reasons for drug attrition during preclinical and clinical 
drug development [1, 2]. Current testing strategies are based on the ICH (International 
Conference on Harmonization) guidelines [3] and employ both rodent and non-rodent 
toxicology studies to limit and manage risk to human volunteers and patients. However, the 
current preclinical testing paradigm may not predict some organ toxicities [1] such as Drug-
Induced Liver Injury (DILI). To date, DILI is one of the primary concerns in drug development and 
is also a frequent cause of regulatory actions like Black Box Warnings or denial in approval [4]. 
Many efforts have been made to improve the ability of preclinical work to predict clinical 
outcome, especially for DILI. 
In Europe, progress has been made towards using alternative means [3, 5] under the 
Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) to evaluate the 
toxicity of chemicals using both in vitro and in silico approaches [6]. The in vitro techniques 
mainly focus on the use of high-throughput screening methodologies to record cellular 
responses simultaneously for multiple chemicals whereas the in silico methods aim to predict 
toxic responses based mainly on structure-toxicity relationships. For both methods, a reference 
list with a large number of compounds is required that classifies chemicals for DILI risk as either 
‘potential to cause liver injury’ or ‘does not cause liver injury’. This reference list is fundamental 
to underpin predictive toxicity efforts along with machine learning techniques that can build a 
profile of DILI negative and DILI positive characteristics[7].  
When high-throughput screening and in silico approaches are applied to a large number of 
drugs, they depend on these drugs being correctly annotated, in this case by a reliable DILI 
classification scheme to identify markers that can distinguish DILI positives from DILI negatives. 
However, categorizing DILI for any given drug is challenging and somewhat controversial; thus, 
it must be approached in a systematic way. Since DILI risk assessment is multifactorial, one 
helpful way to categorize DILI is according to the following characteristics:   
i) causality – does this drug cause DILI? 
ii) incidence – how many individuals are affected and  
iii) severity – the clinical impact for the patient ranging from transient liver enzyme 
elevations through to liver failure (requiring transplantation).  
These three characteristics have to be considered together in order to identify an integrated 
potential DILI risk for a drug [8].  Currently, there are several DILI classification schemes 
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reported [7-13] . Some place much emphasis on incidence in the population but DILI is rare, 
occurring in only a very small number of patients.  Thus, the results derived from incidence-
driven DILI classification vary among investigators perhaps due to under-reporting. Others 
schemes include all three data types outlined above.  For example, the Liver Toxicity 
Knowledge Base (LTKB) project has developed a comprehensive DILI classification scheme and 
the FDA Labeling information balances these three sets of information [13].  
      
2. Liver Toxicity Knowledgebase (LTKB) Overview 
The Liver Toxicity Knowledge Base (LTKB) has been developed at the US Food and Drug 
Administration’s National Center for Toxicological Research (USFDA NCTR) to serve as a 
reference for drug development related research.  Freely available for public use, LTKB is 
designed to assist regulators, researchers and clinicians with their DILI related inquiries. LTKB 
contains DILI classification lists as described previously, in addition to the physio-chemical 
profile for each drug.  In practical terms, LTKB is a warehouse of data that can be used for 
understanding DILI related phenomena, building models to make predictions and for finding 
associations to make inferences from data [7, 8, 13].  
Currently, LTKB includes in vitro and in vivo data from preclinical studies, emerging technology 
data such as gene expression profiles, in silico data such as physico-chemical properties and 
chemical structure descriptors and epidemiology data such as reported adverse events. These 
data can be depicted in different categories such as histopathology, cellular responses, 
toxicogenomics, drug properties, therapeutic uses/side effects and patient response (Figure 1).  
By providing comprehensive information at one location, LTKB provides the opportunity to 
understand the underlying biological complexity of the response to individual or groups of 
drugs.  Since users can perform searches driven by their own requirements, output is tailored to 
the query posed and the results from the queries can be downloaded in spreadsheet format for 
further use. In practical terms, users interrogate LTKB by inserting their specific information in a 
text box for each field. Structure-related searches include similarity, exact match and flexible 
matches.  Searches can also be refined and made more specific using multiple step queries. 
Over 1000 drugs have been incorporated into the database which can be found at 
http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ 
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Figure 1. A summary of data in the Liver Toxicity Knowledge Base (LTKB). Data include DILI 
classification, drug-specific information such as chemical structures and physico-chemical 
properties, in vitro data and toxicogenomics data. The database is being linked to other publicly 
available databases such as ToxCast, Tox21 and LiverTox.   
7 
 
 
3. Resources available in LTKB  
 
3.1  DILIrank – the largest DILI classification dataset 
The LTKB encompasses an approach to classify the DILI potential of drugs based on FDA drug 
labeling information [8]; a total of 1036 FDA drugs approved for human use with a single active 
molecule were included. The analysis focused just on drugs approved by the FDA before 
January 1st 2010 (Table 1) since it generally takes >5 years to collate the required post 
marketing safety information into the label to support a meaningful categorization [13]. Drug 
labeling-based hepatotoxicity information was extracted from three labeling categories: ‘boxed 
warning’ (commonly known as “Black Box Warning”) ‘warnings and precautions’ and ‘adverse 
reactions’. Originally, Chen et al [8] annotated 287 drugs (Table 1) by grouping them into three 
DILI categories (most-, less- and no-DILI-concern). The ‘most-DILI-concern drugs’ were in the 
categories: ’withdrawn drugs due to hepatotoxicity’, drugs with ‘Black-Box Warning’ for 
hepatotoxicity and drugs with high severity noted for hepatotoxicity in ’warnings and 
precautions’. Where ’Warnings and Precautions’ indicated less DILI severity, the drug was 
classified as less-DILI-concern. ‘Adverse Reactions’ drug label was also classified as less-DILI-
concern. In the absence of a hepatotoxicity related drug labeling, the drug was classified as no-
DILI-concern [8]. More recently, this approach was revised and improved by incorporating DILI 
causality [13], which resulted in the DILIrank dataset (Table 1). Specifically, DILIrank contains 
verified (v) annotated as vMost-DILI-Concern, vLess-DILI-Concern and vNo-DILI-concern. The 
fourth category for DILI concern was ‘Ambiguous DILI-concern’, for  drugs where causality 
remains to be established [13].  
3.2 DILIrank versus LiverTox database 
We compared the DILIrank dataset with DILI information from LiverTox (livertox.nih.gov) 
severity scores. LiverTox [14] is a collaborative project between the National Institute of Health, 
National Institute of Diabetes Liver Disease Research Branch and Digestive and Kidney Diseases 
(NIDDK) and the Division of Specialized Information Services of the National Library of Medicine 
(NLM). LiverTox scores are assigned based on the patient’s clinical outcome. This severity level 
(scale of 1-5) was designed to address the clinical spectrum of DILI damage from mild ALT 
elevations (1 on the scale) through to death due to DILI (5 on the scale) (Table 1) [14].  
As shown in Figure 2, the concordance between DILIrank and LiverTox databases was consistent 
only for these drugs in two of the categories. Specifically, there was overlap for  (i) Most-DILI-
Concern (DILIrank) and Fatal 5+ (LiverTox) and (ii) Less-DILI-Concern (DILIrank) and Mild 1+ 
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(LiverTox). For example, 25 out of 34 drugs (74%) causing Fatal DILI (severity level 5+) 
determined by LiverTox were also the Most-DILI-Concern drugs in DILIrank. Similarly, 24 out of 
31 drugs (77%) with Mild DILI signal (severity level 1+) by LiverTox were the Less-DILI-Concern 
drugs by DILI Rank. Importantly, the drugs classified as safe by DILI Rank (i.e., No-DILI-Concern) 
have no DILI case reports collected by LiverTox. Although the general trend in DILI severity is 
apparent between the two databases, the one-to-one concordance was not statistically 
significant. Of note, DILIrank classifies drugs based on the DILI information gathered during drug 
development, clinical trials, approval and post-marketing studies whereas the LiverTox 
classification is based on clinical observation. In addition, the DILI pattern observed in the 
clinical setting described in LiverTox does not necessarily correspond to the severity defined by 
DILIrank. The difference in DILI classification between two databases therefore derives mainly 
from their source information.   
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Figure 2: Comparison of DILIrank with LiverTox database. DILIrank was derived from a drug-
centric DILI classification approach based on FDA drug labeling data whereas the LiverTox-based 
DILI classification is based on clinical observation. Each histogram represents a type of liver 
injury and also the number of drugs in that category reported to have that kind of injury. 
Hepatocellular, cholesteric, mixed and ‘unclear’ types of injury are represented depicted as blue, 
red, green and purple histograms respectively.  No-DILI-Concern is not represented in this figure 
because there were no DILI related case reports collected by LiverTox for that category. 
3.3 Other DILI classification methods in LTKB 
Different reported DILI classifications tend to cover drug lists assembled from different sources, 
resulting in limited overlap in output. DILIrank contains the largest list of drugs annotated 
systematically based on drug labeling information. LiverTox, where DILI classification is 
determined by analyzing the case reports in the literature, is also a sizeable dataset. Besides 
these two datasets, LTKB also collates several other notable DILI classification datasets, 
summarized in Table 1 and described below. 
 
Greene et al. [12] collated case reports for DILI and literature evidence for a total of 325 drugs 
and classified them as follows: 189 drugs with strong evidence for human hepatotoxicity, 50 
drugs with weak evidence and 86 drugs with no evidence. In another published study, Suzuki et 
al. [9] consolidated DILI information for 225 drugs by collating DILI related information from 
major registries such as the Spanish DILI registry, the Swedish adverse reaction databases and 
the DILI network (DILIN) (USA). Finally, Xu et al. [11] collated 217 drugs for DILI causality based 
on case reports and literature information; 161 drugs were identified as DILI positive and 56 
drugs as DILI negative.  Guo et al. [10] collated 47 different drugs and classified them in three 
categories: 32 drugs were identified for severe hepatotoxicity (clear evidence in the literature 
that they endanger life). A further thirteen drugs demonstrated multiple case reports of hepatic 
injury and for 4 there were no reports of significant hepatotoxic damage.  
 
Another interesting consideration is whether some therapeutic categories are overrepresented 
in DILI causation. To assess this, a statistical analysis of incidence according to therapeutic 
category (as obtained from DrugBank [15]) was conducted (Table 1).  Using Fisher's exact test, 
the therapeutic categories that were significantly enriched with DILI related drugs (p-value 
≤0.05) were identified.  The results showed that antineoplastic agents are present in 6 out of 7 
datasets, far more than other therapeutic categories. 
 
Table 1.DILI classifications represented in LTKB 
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No. DILI human 
classificatio
n in LTKB 
DILI Evidence 
information 
No. of 
Drugs* 
Categories Major 
Hepatotoxic 
Therapeutic 
categories**   
1. DILI Rank [12, 
13] 
FDA Drug Labelling and 
DILI causality evidence 
1036 
V
No-DILI-Concern (312) 
V
Less-DILI-Concern 
(278) 
V
Most-DILI-Concern 
(192) 
V
Ambiguous-DILI-
Concern (254)  
Antineoplastic agents 
Antibacterial agents  
2 LiverTox [11, 
14] 
Human DILI Case 
Reports 
694 Non-DILI (98) 
Rare-DILI-Reported (69) 
DILI Literature Evidence 
(273)  
DILI Severity 1+ (40) 2+ 
(16) 3+ (128) 4+(25) 
5+(42) 
Antineoplastic agents 
 
3 Greene et al. 
[12] 
Literature evidence and 
DILI case reports 
325 Human hepatotoxicity 
(189) 
Weak evidence (50) 
No Evidence (86) 
NSAID’s 
4 DILI Benchmark 
Dataset[8] 
FDA Drug Labeling 287 No-DILI-Concern (137) 
Less-DILI-Concern (85) 
Most-DILI-Concern (65) 
Antineoplastic agents 
Antibacterial agents  
5 Suzuki et al. [9] DILI at Physician’s Desk 
reference 
287 General liver injury 
(157) 
Acute liver failure (87) 
withdrawn or 
suspension for DILI (43) 
Antineoplastic agents, 
Antibacterial agents and 
Antihypertensive agents, 
NSAID’s 
6 Xu et al. [11] Literature evidence and 
DILI case reports 
217 DILI Positive (161) 
DILI Negative (56) 
Antineoplastic agents 
NSAID’s
 
7 Guo et al. [10] 5 major US drug 
compendia: American 
Hospital Formulary 
Service (AHFS), United 
States Pharmacopeia 
Drug Information 
(USPDI), Facts and 
Comparisons (F&C), 
Physicians' Desk 
Reference (PDR), and 
Clinical Pharmacology 
(CP) 
86 No information (1) 
No significant liver 
damage (8) 
Significant liver injuries 
(24) 
Life-threatening 
hepatotoxicity (53) 
Antineoplastic agents 
 
* The number of drugs reported from each classification reflects drugs that were approved by 
the FDA before 2010 
** The Therapeutic category is obtained from drug bank. The enrichment analysis is based on 
Fisher’s exact test with p-value less than 0.05. 
 
3.4 In vitro assay data in LTKB  
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In vitro model systems based on human liver-derived tissues such as tissue slices, cell lines or 
primary hepatocytes have been developed to help identify human DILI risk.  Gustafsson et al 
[16] classified 104 drugs for human hepatotoxicity in human hepatocytes overexpressing 
cytochrome P450. Using human hepatocytes, Zhang et al [17] identified severe DILI-causing 
drugs using a composite test based on in vitro measurements of reactive oxygen species (ROS) 
and adenosine triphosphate (ATP). Drugs tested in this system were those that had been 
described as banned, withdrawn, unapproved or severely restricted by European and American 
governments. Zhang et al [17] tested the drug categories that included black box warnings for 
hepatotoxicity or drugs associated with acute liver failure.    
O’Brien et al [18] generated a DILI classification using High Content Biology Screening (HCS) by 
looking at the effects of 300 drugs on various mechanisms of toxicity such as stress pathway 
activation, organelle function, oxidative stress, DNA Damage, Cell Cycle and cytoskeletal 
integrity. For the HCS experiments, HepG2 and primary rat hepatocytes cells were exposed for 
different time intervals representing acute, early and chronic drug level exposures with the 
objective of identifying toxicity biomarkers.  
High-throughput screening (HTS) assays are used extensively in drug discovery as a method for 
identifying small molecule ‘hits’ against a target of interest for potential efficacy. Similarly, HTS 
can be used an as early screen to detect molecules with the potential to cause unacceptable 
toxicity.  One thousand chemicals were tested in 500 different assays for the ToxCast project 
[19] and approximately 10,000 chemicals were tested by 50 different assays for the Tox21 
project [20]. Both ToxCast and Tox21 assay data were connected with the DILI classification 
information in LTKB. LTKB also contains information from approximately 150 compounds tested 
on human hepatocytes to determine DILI potential at the National Center for Toxicological 
Research where several drugs causing severe DILI were identified [17]. 
 
3.5 Toxicogenomics (TGx) in LTKB for DILI prediction  
TGx databases contain information regarding the effect of a drug on the toxicogenomic 
response of targeted organs including liver, kidney, and primary hepatocytes from both rats 
and humans. One of the comprehensive TGx databases is based on microarray gene expression 
profiling conducted in the Japan Toxicogenomics Project [21, 22] 
(http://toxico.nibio.go.jp/open-tggates/search.html.) This TG-GATEs database has been linked 
to DILI information in LTKB. The same approach was also implemented to link LTKB to 
DrugMatrix toxicogenomics data hosted by the National Toxicological Program, National 
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Institute of Environmental Health Sciences (https://ntp.niehs.nih.gov/drugmatrix/index.html). 
[23].  
 
4. Utility of LTKB 
The LTKB provides a centralized repository for data for the study of DILI. Particularly, the DILI 
classification data in LTKB could be a useful resource to connect phenotype with molecular and 
mechanistic data for developing biomarkers, predictive models and assessing data from 
emerging technologies such as high-throughput screening, high-content screening and in silico 
methodologies (Figure 3). For example, bioinformatics approaches [24-28] including Structure-
Activity Relationship (SAR) and Quantitative Structure-Activity Relationship (QSAR) can be used 
to establish a connection between the structures of a chemical and its DILI risk [29]. In one 
study, approximately 500 drugs were analyzed using a QSAR approach [24, 30], where 
molecular descriptors were generated using Mold2 [28], and structure-DILI relationships were 
identified using the Decision Forest algorithm [27]. A second study is developing a DILI 
predictive toxicological approach to identify DILI-associated side effects [24]. Metabolism-
related parameters that have potential to cause DILI [25, 26, 31, 32] are also of interest. 
Importantly, after the identification of essential parameters indicating DILI, a relationship 
model was established to predict DILI called “Rule of Two” [31] which flags each drug for its DILI 
potential based on its lipophilicity (measured by its logP > 3) and a daily dose of > 100 mg/day.  
More recently, DILI severity quantitative scores were developed on the basis of a drug’s 
lipophilicity,  daily dose, and its capability to form metabolites [32].  
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Figure3. Key methodologies that require a large drug reference list for assessing toxicity. Most 
of these methods are employed to screen simultaneously hundreds of drugs to assess DILI 
potential. LTKB integrates information generated from all these methodologies into one tool 
that can be interrogated. 
 
5. Expert Commentary  
Liver toxicity is a multifactorial problem and its prediction is challenging due to the diverse 
mechanisms involved in the causation of DILI. One of the major issues is a lack of translation of 
preclinical data to clinical findings; this poses challenges in interpretation of preclinical data to 
assess and predict human risk. This may be improved by including clinical severity information 
for known drugs into models that predict DILI. Another important aspect is how drugs interact 
with individual patients, sometimes generating idiosyncratic DILI associated with specific risk 
factors, often with an underlying immune-mediated mechanism.   A more complete 
understanding of the dataset can be obtained by integration of all drug information such as 
chemical structures and properties with toxicogenomics information, in vitro and in vivo 
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information. This integration not only provides a complete preclinical picture for a particular 
drug, it may also help to understand the responses to a drug at various level of complexity from 
drug properties, genomic signals and cellular response to in vivo observations.  
A second key issue is that it is vital to understand and incorporate more sophisticated 
descriptors of clinical outcome of liver injury into predictive models. Currently, most DILI 
studies center on a simple prediction of DILI severity but DILI has multiple complexities such as 
the different types of injury patterns, pathologies and associated clinical progression. It is 
important that we develop the ability to predict different types of DILI that may be associated 
with disease severity. Furthermore, it would be highly valuable to incorporate into predictions 
the observations that some therapeutic drug categories are more prone or predisposed to liver 
injury related issues, and that some drugs can cause damage to multiple organs.   
 
6. Five Year View  
The next five years will inevitably feature significant advances in computation and automation 
in this field. As depicted in Figure 4, much progress has been made in our ability to assess DILI 
severity and many drugs (>1000 drugs in LTKB) have been classified by their probability to cause 
DILI. With advancements in the accuracy of DILI classification, model accuracy will also increase. 
This knowledge will drive the enhanced prediction of not only DILI severity, but also DILI 
patterns and disease types. Another key development could be automatic inclusion into the 
database of DILI-related FDA labeling information and post-marketing data available at the FDA 
Adverse Events Reporting System (FAERS) to build content and enhance the DILI classification 
system. With the continuing growth of diverse data in LTKB, an ultimately aim would be 
integration of progressively diverse datasets from multiple sources and technologies for 
improved DILI assessment. 
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Figure 4. A schematic projection of currently established DILI related technologies and their 
status in the upcoming 5 years. Arrows depict estimations of the future developments for each 
approach from the current day to full potential. 
7. Summary 
With the rapid advancements in in vitro, in silico, HTS, and HCS technologies, it is becoming 
more important than ever to have an accurate classification of toxicological endpoints (such as 
DILI) covering a large number of drugs and drug classes. With this in mind, different DILI 
classifications can be integrated to provide a more comprehensive understanding of DILI. The 
scientific community is united in its desire to define the likelihood of a drug causing liver injury 
but different approaches have been taken to quantify DILI risk. As a result, there are many 
different ways of characterizing DILI and many different approaches to the development of 
biomarkers based both on traditional techniques and on the use of emerging technologies such 
as HTS, HCT and TGx. Many of these biomarkers remain to be validated, confounded by some of 
the inaccurate or unhelpful classifications of DILI. LTKB integrates and compares DILI 
terminology and classification. Highlighting the inclusion of DILI related information in LTKB 
provides the opportunity for a comprehensive understanding and analysis of various available 
DILI classifications. This is the first time that such a detailed analysis of different sources and 
types of DILI-related information has been presented.  
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While the LTKB can be effective in supporting the development of predictive models for DILI, it 
also provides assistance in improving our understanding of underlying mechanisms of DILI. It 
offers centralized information on DILI including its biological complexity and users can see ‘at a 
glance’ all the available DILI information. This is a useful resource for researchers, clinicians and 
regulators permitting a rapid assessment of DILI related risk but also as a prompt to consider 
mechanisms and severity. This knowledgebase provides opportunities for researchers building 
integrated models for predicting DILI, provides support for reviewers making DILI related 
queries, and serves clinicians as a DILI resource. 
8. Key issues: 
 A comprehensive drug list accurately classified for its potential to cause human liver 
injury is an important resource to support drug-induced liver injury (DILI) studies.  
 DILI classification raises substantial challenges since the topic is controversial; different 
publications and databases have used different methods raising the need for 
harmonization and integration.  
 With increasing demand for quick turn-around procedures to predict DILI, high-
throughput and in silico approaches are being used in this field. Centralized DILI related 
information can provide a ‘one-stop-shop’ to address key questions like risk of DILI and 
its incidence and severity.   
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